Diffusion Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference
September 11 2020 - 8:30AM
Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN)
(“Diffusion” or “the Company”), today announced its management will
present at the H.C. Wainwright 22nd Annual Global Investment
Conference to be held virtually on September 14-16, 2020. Robert
Cobuzzi, Ph.D., chief executive officer, will present a corporate
overview of the Company on Tuesday, September 15th, at 3:00 p.m.
Eastern time.
A link to the live webcast of the presentation
will be available online through the investor relations section of
Diffusion’s website here. Following the event, a replay of
the presentation will be archived on the Diffusion website for
approximately 90 days.
About Diffusion Pharmaceuticals
Inc.
Diffusion Pharmaceuticals Inc. is an innovative
biotechnology company developing new treatments that improve the
body’s ability to deliver oxygen to the areas where it is needed
most, offering new hope for the treatment of life-threatening
medical conditions. Diffusion’s lead drug TSC was originally
developed in conjunction with the United States (“U.S.”) Office of
Naval Research, which was seeking a way to treat multiple organ
failure and its resulting mortality caused by low oxygen levels
from blood loss on the battlefield. Today, Diffusion is focused on
addressing some of medicine’s most intractable and
difficult-to-treat diseases, including multiple organ failure from
respiratory distress related to diseases such as COVID-19, stroke
and glioblastoma multiforme (“GBM”). In each of these diseases,
lack of available oxygen presents a significant obstacle for
medical providers and is the target for TSC’s novel mechanism. The
Company is currently partnering with U.S. and European institutions
on an expedited research program to develop TSC as a treatment for
the low oxygen levels and associated multiple organ failure in
COVID-19 patients.
Preclinical data support the potential for TSC
as a treatment for other conditions where low oxygen availability
plays an important role, such as myocardial infarction, peripheral
artery disease and neurodegenerative conditions such as Alzheimer’s
and Parkinson’s disease. In addition to the development of
TSC, RES-529, the Company’s PI3K/AKT/mTOR pathway inhibitor that
dissociates the mTORC1 and mTORC2 complexes, is in preclinical
testing for GBM.
Diffusion is headquartered in Charlottesville,
Virginia – a hub of advancement in the life science and
biopharmaceutical industries.
Contacts:Robert Cobuzzi, Ph.D.,
CEODiffusion Pharmaceuticals Inc.(434)
220-0718rcobuzzi@diffusionpharma.com
LHA Investor RelationsKim Sutton Golodetz(212)
838-3777kgolodetz@lhai.com
Media Contact:Jeffrey
FreedmanRooneyPartners646-432-0191jfreedman@rooneyco.com
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Sep 2023 to Sep 2024